Ozaki S.,Fuji Sangyo Co.
Journal of agricultural and food chemistry | Year: 2010
An arabinogalactan-protein (WSSP-AGP) was isolated from the tuberous cortex of the white-skinned sweet potato (WSSP; Ipomoea batatas L.). It consists of 95% (w/w) carbohydrate and 5% (w/w) protein with high contents of hydroxyproline, alanine, and serine. Its sugar composition is α-L-Rha:α-L-Ara:β-D-Gal:β-D-GlcA in a molar ratio of 1.0:4.1:7.6:1.3. Its weight-average molecular weight was estimated to be 126,800 g/mol by high-performance size exclusion chromatography coupled with multiangle laser light scattering. Structural analysis indicated that WSSP-AGP is a (1→3)-β-D-galactan highly branched at O-6 with (1→6)-β-D-galactan, in which the branched chains are substituted at the O-3 position with α-L-Araf-(1→ and α-L-Araf-(1→5)-α-L-Araf-(1→ and at the O-6 position typically with α-L-Rhap-(1→4)-β-D-GlcAp-(1→ as terminating groups. Continuous administration of WSSP-AGP to KKAy mice significantly lowered fasting plasma glucose levels. This indicates that WSSP-AGP plays an important role in the hypoglycemic effects of WSSP.
Kokubo Y.,Kinjo Gakuin University |
Yokoyama Y.,Tokyo University of Agriculture |
Yokoyama Y.,Japan Society for the Promotion of Science |
Kisara K.,Japan Womens College of Physical Education |
And 8 more authors.
International Journal of Sport Nutrition and Exercise Metabolism | Year: 2016
This cross-sectional study explored the prevalence of iron deficiency (ID) and associations between dietary factors and incidence of ID in female rhythmic gymnasts during preseason periods. Participants were 60 elite collegiate rhythmic gymnasts (18.1 ± 0.3 years [M ± SD]) who were recruited every August over the course of 8 years. Participants were divided into 2 groups according to the presence or absence of ID. Presence of ID was defined either by ferritin less than 12 μg/L or percentage of transferrin saturation less than 16%. Anthropometric and hematologic data, as well as dietary intake, which was estimated via a semiquantitative food frequency questionnaire, were compared. ID was noted in 48.3% of participants. No significant group-dependent differences were observed in physical characteristics, red blood cell counts, hemoglobin, hematocrit, haptoglobin, or erythropoietin concentrations. The ID group had a significantly lower total iron-binding capacity; serumfree iron; percentage of transferrin saturation; ferritin; and intake of protein, fat, zinc, vitamin B2, vitamin B6, beans, and eggs but not iron or vitamin C. The recommended dietary allowance for intake of protein, iron, zinc, and various vitamins was not met by 30%, 90%, 70%, and 22%-87% of all participants, respectively. Multiple logistic analysis showed that protein intake was significantly associated with the incidence of ID (odds ratio = 0.814, 95% confidence interval [0.669, 0.990], p = .039). Participants in the preseason's weightloss periods showed a tendency toward insufficient nutrient intake and were at a high risk for ID, particularly because of lower protein intake. Copyright © 2016 Watam Press.
Fuji Sangyo Co. | Date: 1999-11-22
Food supplements; dietary food supplements; dietetic supplements adapted for medical use; food for diabetics; health food in the nature of food for maintaining or improving the health of a person, namely, processed sweet potatoes, having the botanical name of Ipomoea batas L., in powdered tablets, granules and capsule form, for use as a dietary supplement or a meal replacement.
Fuji Sangyo Co. | Date: 2010-03-08
A method for producing an orally ingestible composition containing an arabinofuranosyl vitexin and/or a hydrolysate thereof by using
Fuji Sangyo Co. | Date: 2004-10-18
Food supplements; dietary food supplements; dietetic supplements adapted for medical use; food for diabetics; health food in the nature of food for maintaining or improving the health of a person, namely, processed sweet potatoes having the botanical name of Ipomoea batatas L;, in powdered tablets, granules and capsule form, for use as a dietary supplement, drugs for medical purposes for treating lifestylerelated disease such as diabetes; medicines for human purposes for treating lifestyle-related disease such as diabetes; and pharmaceutical preparations for treating lifestylerelated disease such as diabetes.